FrankStephenHodiJr.MD

Oncology • Boston, MA

Melanoma

Professor of Medicine, Harvard Medical School Dana-Farber Cancer Institute

Join to view full profile

Dr. Hodi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hodi's full profile

Already have an account?

Office
450 Brookline Avenue
Dana Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-5053

Fax+1 617-582-7992
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
University of Pennsylvania Health SystemResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1995 - 2025
PA State Medical License 1994 - 1996
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Elected Member The American Society for Clinical Investigation, 2012

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer Start of enrollment: 2002 Mar 01
Terminated
Phase 1
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma Start of enrollment: 2002 Sep 01
Completed
Not Applicable
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma Start of enrollment: 2005 Jan 01
Completed
Phase 1
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma Start of enrollment: 2006 Jul 01
Completed
Phase 2
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Start of enrollment: 2007 Aug 01
Completed
Phase 2
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 1
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma Start of enrollment: 2009 Feb 26
Completed
Phase 1
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) Start of enrollment: 2003 Oct 16
Active, not recruiting
Phase 1
Dinaciclib in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2009 Sep 01
Terminated
Phase 1, Phase 2
Panobinostat (LBH589) in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01
Completed
Phase 1
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2010 Dec 28
Active, not recruiting
Phase 2
STA-9090(Ganetespib) in Metastatic Ocular Melanoma Start of enrollment: 2010 Sep 17
Completed
Phase 2
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2011 Sep 01
Terminated
Phase 2
Dendritic Cell Activating Scaffold in Melanoma Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 1
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) Start of enrollment: 2013 Apr 30
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine EC...
Walter, A., Lee, J., Streck, J., Gareen, I., Herman, B., Kircher, S., Carlos, R., Kumar, S., Mayer, I., Saba, N., Fenske, T., Neal, J., Atkins, M., Hodi, F., Kyriakopo...> ;Cancer. 2024 Feb 1
53 citations
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer, Piotr Rutkowski, Le...> ;Journal of Clinical Oncology. 2023 Jan 20
329 citations
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
, , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2021 Nov 24
8 citations
Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
Livius Penter, Satyen H. Gohil, Teddy Huang, Emily M. Thrash, Dominik Schmidt, Shuqiang Li, Mariano Severgnini, Donna Neuberg, F. Stephen Hodi, Kenneth J. Livak, Rober...> ;Blood Advances. 2021 Nov 23
10 citations
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial.
Vincent T. Ho, Haesook T. Kim, Jennifer Brock, Ilene Galinsky, Heather Daley, Carol Reynolds, Augustine Weber, Olga Pozdnyakova, Mariano Severgnini, Sarah Nikiforow, C...> ;Blood Advances. 2021 Nov 22
40 citations
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, ph...
Nehal Lakhani, Laura Q.M. Chow, Justin F. Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Yung-Jue Bang, F.S. Hodi, Won Seog Kim, Rafael Santana...> ;The Lancet. Oncology. 2021 Nov 15
98 citations
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label...
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, F. Stephen Hodi, Alain Algazi, Omid Hamid, Christopher D. Lao, Stergios J. Moschos, Michael B. Atkins, Karl D. Lewis, Mic...> ;The Lancet. Oncology. 2021 Nov 10
24 citations
SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis.
Satoru Yokoyama, Atsushi Takahashi, Ryota Kikuchi, Soshi Nishibu, Jennifer A. Lo, Miroslav Hejna, Wooyoung M. Moon, Shinichiro Kato, Yue Zhou, F. Stephen Hodi, Jun S. ...> ;Cancer Research. 2021 Nov 2
12 citations
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M. Regan, Charlene Mantia, Lillian Werner, Ahmad A. Tarhini, James Larkin, F. Stephen Hodi, Michael A. Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings,...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
8 citations
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A. Ott, Matthew Nazzaro, Kathleen L. Pfaff, Evisa Gjini, Kristen Felt, Jacquelyn O. Wolff, Elizabeth I. Buchbinder, Rizwan Haq, Ryan J. Sullivan, Donald P. Law...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
82 citations
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas.
Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying C...> ;Clinical Cancer Research. 2021 Oct 29
26 citations
Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
Michael Li, Danny Wong, Alexander S Vogel, Jordan Sack, Osama E. Rahma, F. Stephen Hodi, Stephen D. Zucker, Shilpa Grover> ;Hepatology. 2021 Oct 28
26 citations
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Jianda Yuan, Anuradha D. Khilnani, Joshua Brody, Robert H.I. Andtbacka, Siwen Hu-Lieskovan, Jason J. Luke, Adi Diab, Aurélien Marabelle, Alexandra Snyder, Z. Alexander...> ;European Journal of Cancer. 2021 Sep 21
59 citations
Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors.
Megan L. Burger, Amanda M. Cruz, Grace E. Crossland, Giorgio Gaglia, Cecily C. Ritch, Sarah E. Blatt, Arjun Bhutkar, David Canner, Tamina Kienka, Sara Z. Tavana, Alexi...> ;Cell. 2021 Sep 16
1 citations
Erratum: A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer...
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbo...> ;Clinical Cancer Research. 2021 Sep 1
4 citations
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Settin...
Girish S. Naik, Elizabeth I. Buchbinder, Justine V. Cohen, Michael Manos, Alistair E. W. Johnson, Peter Bowling, Ayal A. Aizer, Jonathan D. Schoenfeld, Donald P. Lawre...> ;Journal of Immunotherapy. 2021 Aug 18
61 citations
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
F. Stephen Hodi, Dirk Schadendorf, James Larkin, Georgina V. Long, Xiaozhong Qian, Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang, Hao Tang, Megan Wind-Rotolo...> ;Cancer Immunology Research. 2021 Aug 13
123 citations
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, ...> ;Clinical Cancer Research. 2021 Jul 1
20 citations
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients.
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen L. Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain> ;NPJ Precision Oncology. 2021 Jun 29
44 citations
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.
Elio Adib, Amin Nassar, Elie W. Akl, Sarah Abou Alaiwi, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Guru Sonpavde, Robert I. Haddad, Kent W. Mouw, Marios Giannakis, F. St...> ;Clinical Cancer Research. 2021 Jun 1
10 citations
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, Harriet M. Kluger, Zeynep Eroglu, Henry B. ...> ;Journal for Immunotherapy of Cancer. 2021 May 1
54 citations
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Hussein Abdul-Hassan Tawbi, Peter A. Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, Joh...> ;Neuro-Oncology. 2021 Apr 21
21 citations
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Livius Penter, Yi Zhang, Alexandra Savell, Teddy Huang, Nicoletta Cieri, Emily M. Thrash, Seunghee Kim-Schulze, Aashna Jhaveri, Jingxin Fu, Srinika Ranasinghe, Shuqian...> ;Blood. 2021 Jun 10
5 citations
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patric...> ;Cancer Medicine. 2021 Mar 15
37 citations
Expression of T-cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for response to Nivolumab in Metastatic Clear Cell Renal Cell Carc...
Miriam Ficial, Opeyemi Jegede, Miriam Sant'Angelo, Yue Hou, Abdallah Flaifel, Jean-Christophe Pignon, David A. Braun, Megan Wind-Rotolo, Maura Sticco-Ivins, Paul J. Ca...> ;Clinical Cancer Research. 2021 Mar 1
Join now to see all

Journal Articles

Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

Hospital Affiliations

Brigham and Women's HospitalBoston, Massachusetts
Salem HospitalSalem, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts